Prometheus Biosciences, Inc.
RXDX
Ранг среди акций
#3256
Prometheus Biosciences, Inc. is a biopharmaceutical company primarily focused... Prometheus Biosciences, Inc. is a biopharmaceutical company primarily focused on discovering, developing, and commercializing innovative therapeutics and complementary diagnostic products, mainly targeting inflammatory bowel diseases (IBD). Its flagship therapeutic candidate, PRA023, is a humanized IgG1 monoclonal antibody currently undergoing Phase IIa clinical trials. This investigational treatment is being evaluated for its potential in addressing ulcerative colitis and Crohn's disease, both forms of IBD, as well as systemic sclerosis-associated interstitial lung disease. Beyond its lead asset, Prometheus maintains an active development pipeline featuring several other programs targeting IBD and other immune-mediated conditions: PR600: An anti-tumor necrosis factor monoclonal antibody (mAb) for IBD. PR300: A small molecule G-protein coupled receptor modulator specifically for IBD. PR1100: An anti-cytokine receptor mAb with applications in IBD and various other immune disorders. PR1800: An anti-chemokine mAb focused on IBD. PR2100: An anti-inflammatory cytokine mAb also aimed at IBD. Furthermore, the company has forged key alliances, including a diagnostic development and collaboration pact with Takeda Pharmaceutical Company Limited, a co-development and manufacturing arrangement with Dr. Falk Pharma GmbH, a licensing agreement with Cedars-Sinai Medical Center, and a strategic partnership with Millennium Pharmaceuticals, Inc. Tracing its origins, the company was initially incorporated in 2016 as Precision IBD, Inc., before rebranding to Prometheus Biosciences, Inc. in October 2019. Its corporate headquarters are situated in San Diego, California.
Цена акции
$199.92
Последняя синхронизация: 2023-06-15
Рыночная капитализация
$5.39B
Изменение (1 день)
0.09%
Изменение (1 год)
0.00%
Страна
US
Торговля Prometheus Biosciences, Inc. (RXDX)
Категория
Healthcare
Количество находящихся в обращении акций Prometheus Biosciences, Inc. (RXDX)
Количество акций в обращении на October 2026: 0
Согласно последним финансовым отчетам и цене акций Prometheus Biosciences, Inc., текущее количество акций в обращении составляет 0. На конец October 2026 у компании было 0 акций в обращении. Количество акций в обращении обычно зависит от сплитов и обратного выкупа акций.
История количества акций в обращении Prometheus Biosciences, Inc. (RXDX) с 2014 по 2026
Акции в обращении на конец каждого года
| Год | Акции в обращении | Изменить |
|---|---|---|
| 2022 | 40.62M | 29.63% |
| 2021 | 31.33M | -9.46% |
| 2020 | 34.61M | 28.25% |
| 2019 | 26.98M | -29.87% |
| 2016 | 38.48M | 43.29% |
| 2015 | 26.85M | 46.52% |
| 2014 | 18.33M | 0.00% |
Акции в обращении у аналогичных компаний или конкурентов
| Компания | Акции в обращении | Разница | Страна |
|---|---|---|---|
| 253.90M | - |
US
|
|
| 396.00M | - |
US
|
|
| 478.91M | - |
AU
|
|
| 0.00 | - |
BE
|
|
| 62.19M | - |
NL
|
